[{"id":"a435469f-1cf1-4b7f-a476-32a5089846f8","acronym":"PIVOT IO 011","url":"https://clinicaltrials.gov/study/NCT04540705","created_at":"2021-01-18T21:43:33.570Z","updated_at":"2024-07-02T16:35:17.512Z","phase":"Phase 1","brief_title":"A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread","source_id_and_acronym":"NCT04540705 - PIVOT IO 011","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • axitinib • bempegaldesleukin (NKTR-214)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 09/11/2020","start_date":" 09/11/2020","primary_txt":" Primary completion: 01/18/2024","primary_completion_date":" 01/18/2024","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2024-02-28"},{"id":"9eef6015-0524-41a2-ad75-5ca92817fddd","acronym":"PIVOT IO 001","url":"https://clinicaltrials.gov/study/NCT03635983","created_at":"2022-12-19T18:58:34.707Z","updated_at":"2024-07-02T16:35:33.001Z","phase":"Phase 3","brief_title":"A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma","source_id_and_acronym":"NCT03635983 - PIVOT IO 001","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • bempegaldesleukin (NKTR-214)"],"overall_status":"Completed","enrollment":" Enrollment 783","initiation":"Initiation: 09/21/2018","start_date":" 09/21/2018","primary_txt":" Primary completion: 11/19/2021","primary_completion_date":" 11/19/2021","study_txt":" Completion: 09/06/2023","study_completion_date":" 09/06/2023","last_update_posted":"2023-10-18"},{"id":"ed797c5f-25d7-4b1a-8d37-1d66c1bd4340","acronym":"PIVOT-10","url":"https://clinicaltrials.gov/study/NCT03785925","created_at":"2021-01-18T18:43:19.347Z","updated_at":"2025-02-25T14:27:55.845Z","phase":"Phase 2","brief_title":"A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer","source_id_and_acronym":"NCT03785925 - PIVOT-10","lead_sponsor":"Nektar Therapeutics","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • bempegaldesleukin (NKTR-214)"],"overall_status":"Completed","enrollment":" Enrollment 192","initiation":"Initiation: 04/29/2019","start_date":" 04/29/2019","primary_txt":" Primary completion: 02/09/2022","primary_completion_date":" 02/09/2022","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2023-03-28"}]